Nomograms May Be Useful for Predicting Survival Survival in Non-metastatic Osteosarcoma

Share this content:

the Cancer Therapy Advisor take:

Age, tumor site, and histologic response were determined to be stronger influences on metastasis-free survival (MFS) and overall survival (OS) for patients with nonmetastatic osteosarcoma compared to sex, tumor size, and pathologic fracture, according to an article published online in the journal Cancer.


A total of 1,070 patients who received neoadjuvant chemotherapy and surgery for nonmetastatic osteosarcoma were studied.

The authors developed multivariate nomograms based on data from Japanese patients (n=557). The nomograms were developed to estimate the probability of MFS and OS 3 and 5 years post-diagnosis using six clinical and pathologic variables.


The nomogram model was validated internally for discrimination and also validated externally using an independent patient sample from Korea (n=513).


Results showed factors with stronger influences on MFS and OS included a patient’s age, tumor location, and histologic response, compared to patient’s sex, tumor size, or pathologic fracture.


The authors concluded that the nomograms predicted the probability of both MFS (concordance index, 0.631) and OS (concordance index, 0.679) well. MFS had a concordance index of 0.682 for external validation, and OS had an index of 0.665.


The study suggests its findings verify the usefulness of nomograms for predicting MFS and OS and for assessing postoperative prognosis.

Given the similar outcomes, integrating effective systemic therapy before chemoradiation and surgery
Age, tumor site, and histologic response determined to be stronger influences on metastasis-free, overall survival for nonmetastatic osteosarcoma.
Additional Information How to Cite Ogura, K., Fujiwara, T., Yasunaga, H., Matsui, H., Jeon, D.-G., Cho, W. H., Hiraga, H., Ishii, T., Yonemoto, T., Kamoda, H., Ozaki, T., Kozawa, E., Nishida, Y., Morioka, H., Hiruma, T., Kakunaga, S., Ueda, T., Tsuda, Y., Kawano, H. and Kawai, A.
READ FULL ARTICLE From Wiley Online Library

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs